CA2768576C - Use of stem cells to reduce leukocyte extravasation - Google Patents
Use of stem cells to reduce leukocyte extravasation Download PDFInfo
- Publication number
- CA2768576C CA2768576C CA2768576A CA2768576A CA2768576C CA 2768576 C CA2768576 C CA 2768576C CA 2768576 A CA2768576 A CA 2768576A CA 2768576 A CA2768576 A CA 2768576A CA 2768576 C CA2768576 C CA 2768576C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell
- endothelial
- multistem
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 71
- 210000000265 leukocyte Anatomy 0.000 title abstract description 94
- 206010015866 Extravasation Diseases 0.000 title abstract description 28
- 230000036251 extravasation Effects 0.000 title abstract description 28
- 210000004027 cell Anatomy 0.000 claims abstract description 506
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 152
- 230000014509 gene expression Effects 0.000 claims abstract description 95
- 238000000034 method Methods 0.000 claims abstract description 83
- 230000002829 reductive effect Effects 0.000 claims abstract description 26
- 210000004602 germ cell Anatomy 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims description 73
- 102100023471 E-selectin Human genes 0.000 claims description 60
- 108010024212 E-Selectin Proteins 0.000 claims description 58
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 56
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 56
- 230000004913 activation Effects 0.000 claims description 33
- 102000004127 Cytokines Human genes 0.000 claims description 32
- 108090000695 Cytokines Proteins 0.000 claims description 32
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 23
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 20
- 108010035766 P-Selectin Proteins 0.000 claims description 18
- 102100023472 P-selectin Human genes 0.000 claims description 17
- 210000001185 bone marrow Anatomy 0.000 claims description 17
- 210000001654 germ layer Anatomy 0.000 claims description 16
- 108010002352 Interleukin-1 Proteins 0.000 claims description 15
- 108010017842 Telomerase Proteins 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 11
- 101710150336 Protein Rex Proteins 0.000 claims description 8
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 7
- 238000007876 drug discovery Methods 0.000 claims description 7
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 abstract description 39
- 206010061218 Inflammation Diseases 0.000 abstract description 38
- 230000001413 cellular effect Effects 0.000 abstract description 24
- 230000004069 differentiation Effects 0.000 abstract description 16
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 abstract description 8
- 230000009467 reduction Effects 0.000 abstract description 7
- 230000002222 downregulating effect Effects 0.000 abstract description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 5
- 210000000440 neutrophil Anatomy 0.000 description 61
- 210000001519 tissue Anatomy 0.000 description 47
- 238000003556 assay Methods 0.000 description 40
- 230000036515 potency Effects 0.000 description 34
- 230000027455 binding Effects 0.000 description 31
- 239000002609 medium Substances 0.000 description 31
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 27
- 238000011282 treatment Methods 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 23
- 230000003827 upregulation Effects 0.000 description 23
- 238000003501 co-culture Methods 0.000 description 20
- 238000001727 in vivo Methods 0.000 description 20
- 108010044426 integrins Proteins 0.000 description 20
- 102000006495 integrins Human genes 0.000 description 20
- 239000003446 ligand Substances 0.000 description 20
- 230000008595 infiltration Effects 0.000 description 18
- 238000001764 infiltration Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 17
- 210000001671 embryonic stem cell Anatomy 0.000 description 17
- 230000007423 decrease Effects 0.000 description 16
- 230000003511 endothelial effect Effects 0.000 description 16
- -1 selectin carbohydrate Chemical class 0.000 description 15
- 102000000589 Interleukin-1 Human genes 0.000 description 14
- 102000003800 Selectins Human genes 0.000 description 14
- 108090000184 Selectins Proteins 0.000 description 14
- 239000003636 conditioned culture medium Substances 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 210000001082 somatic cell Anatomy 0.000 description 14
- 230000006378 damage Effects 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 238000005096 rolling process Methods 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 208000014674 injury Diseases 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 206010000891 acute myocardial infarction Diseases 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000008672 reprogramming Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 102000016387 Pancreatic elastase Human genes 0.000 description 10
- 108010067372 Pancreatic elastase Proteins 0.000 description 10
- 108091023040 Transcription factor Proteins 0.000 description 10
- 102000040945 Transcription factor Human genes 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000003038 endothelium Anatomy 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 102100021333 Alpha-(1,3)-fucosyltransferase 7 Human genes 0.000 description 9
- 102000019034 Chemokines Human genes 0.000 description 9
- 108010012236 Chemokines Proteins 0.000 description 9
- 102100038591 Endothelial cell-selective adhesion molecule Human genes 0.000 description 9
- 206010061216 Infarction Diseases 0.000 description 9
- 210000002459 blastocyst Anatomy 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000007115 recruitment Effects 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 101000819497 Homo sapiens Alpha-(1,3)-fucosyltransferase 7 Proteins 0.000 description 8
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 8
- 108010092694 L-Selectin Proteins 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000020411 cell activation Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000003828 downregulation Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 210000001178 neural stem cell Anatomy 0.000 description 8
- 230000002685 pulmonary effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 7
- 102100030931 Ladinin-1 Human genes 0.000 description 7
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 7
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 7
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 101000882622 Homo sapiens Endothelial cell-selective adhesion molecule Proteins 0.000 description 6
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 6
- 102100033467 L-selectin Human genes 0.000 description 6
- 108010054395 P-selectin ligand protein Proteins 0.000 description 6
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 210000004700 fetal blood Anatomy 0.000 description 6
- 208000024908 graft versus host disease Diseases 0.000 description 6
- 230000004217 heart function Effects 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000003716 mesoderm Anatomy 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101100260031 Homo sapiens TBX21 gene Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 5
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 5
- 206010043276 Teratoma Diseases 0.000 description 5
- 210000004504 adult stem cell Anatomy 0.000 description 5
- NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 230000003399 chemotactic effect Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 210000001900 endoderm Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 230000032954 positive regulation of cell adhesion Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000000392 somatic effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 4
- 102100035716 Glycophorin-A Human genes 0.000 description 4
- 108091005250 Glycophorins Proteins 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 4
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 4
- 108010064064 Junctional Adhesion Molecules Proteins 0.000 description 4
- 102000014748 Junctional Adhesion Molecules Human genes 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000035605 chemotaxis Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000001143 conditioned effect Effects 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 238000010449 nuclear transplantation Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000024905 CD99 Human genes 0.000 description 3
- 108060001253 CD99 Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101710129627 Endothelial cell-selective adhesion molecule Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100034223 Golgi apparatus protein 1 Human genes 0.000 description 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000002403 aortic endothelial cell Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 238000011198 co-culture assay Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 108010073382 cysteine-rich fibroblast growth factor receptor Proteins 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 210000003981 ectoderm Anatomy 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 210000003989 endothelium vascular Anatomy 0.000 description 3
- 210000002304 esc Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000037906 ischaemic injury Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000001608 teratocarcinoma Diseases 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000009042 Anterior Wall Myocardial Infarction Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 108091008102 DNA aptamers Proteins 0.000 description 2
- 206010051392 Diapedesis Diseases 0.000 description 2
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 108010072255 Integrin alpha3beta1 Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- 102000016551 L-selectin Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 102100040557 Osteopontin Human genes 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 101150086694 SLC22A3 gene Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 208000033774 Ventricular Remodeling Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 2
- 201000009658 anterolateral myocardial infarction Diseases 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000007321 biological mechanism Effects 0.000 description 2
- 210000001109 blastomere Anatomy 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000032459 dedifferentiation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 2
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000000472 morula Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000030786 positive chemotaxis Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- INZOTETZQBPBCE-NYLDSJSYSA-N 3-sialyl lewis Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@H](O)CO)[C@@H]([C@@H](NC(C)=O)C=O)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 INZOTETZQBPBCE-NYLDSJSYSA-N 0.000 description 1
- 102100021335 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 9 Human genes 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 102400001318 Adrenomedullin Human genes 0.000 description 1
- 101800004616 Adrenomedullin Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 101710188695 Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101710188694 Alpha-(1,3)-fucosyltransferase 7 Proteins 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 208000036490 Arterial inflammations Diseases 0.000 description 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108010086291 Deubiquitinating Enzyme CYLD Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000012545 EGF-like domains Human genes 0.000 description 1
- 108050002150 EGF-like domains Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 229940121889 Endothelin A receptor antagonist Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 1
- 102100021453 Histone deacetylase 5 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000819503 Homo sapiens 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 9 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 1
- 108010041014 Integrin alpha5 Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000017761 Interleukin-33 Human genes 0.000 description 1
- 108010067003 Interleukin-33 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000030514 Leukocyte adhesion deficiency type II Diseases 0.000 description 1
- 208000000706 Leukocyte-Adhesion Deficiency Syndrome Diseases 0.000 description 1
- 102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100038610 Myeloperoxidase Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 101150044441 PECAM1 gene Proteins 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102100024250 Ubiquitin carboxyl-terminal hydrolase CYLD Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102000003970 Vinculin Human genes 0.000 description 1
- 108090000384 Vinculin Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 102100021135 Zinc finger and BTB domain-containing protein 32 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- HBBOZFUQJDYASD-LPHOMBEVSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O HBBOZFUQJDYASD-LPHOMBEVSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000013354 cell banking Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010372 cloning stem cell Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108091007231 endothelial receptors Proteins 0.000 description 1
- 239000003062 endothelin A receptor antagonist Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108010001671 galactoside 3-fucosyltransferase Proteins 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 108010074724 histone deacetylase 3 Proteins 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003318 immunodepletion Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 1
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000000998 lymphohematopoietic effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000010373 organism cloning Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003822 preparative gas chromatography Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000007830 receptor-based assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 210000004269 weibel-palade body Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4232—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4234—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22730909P | 2009-07-21 | 2009-07-21 | |
| US61/227,309 | 2009-07-21 | ||
| PCT/US2010/042726 WO2011011500A1 (en) | 2009-07-21 | 2010-07-21 | Use of stem cells to reduce leukocyte extravasation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2768576A1 CA2768576A1 (en) | 2011-01-27 |
| CA2768576C true CA2768576C (en) | 2022-12-06 |
Family
ID=43497499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2768576A Active CA2768576C (en) | 2009-07-21 | 2010-07-21 | Use of stem cells to reduce leukocyte extravasation |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20110020293A1 (enExample) |
| EP (2) | EP3831930A1 (enExample) |
| JP (7) | JP6243119B2 (enExample) |
| KR (2) | KR20180014224A (enExample) |
| CN (2) | CN104962512B (enExample) |
| AU (1) | AU2010276201B2 (enExample) |
| BR (1) | BR112012001329B1 (enExample) |
| CA (1) | CA2768576C (enExample) |
| DK (1) | DK2456853T3 (enExample) |
| IL (1) | IL217648B (enExample) |
| SG (3) | SG10201913624YA (enExample) |
| WO (1) | WO2011011500A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009205886B2 (en) | 2008-01-18 | 2015-08-27 | Katholieke Universiteit Leuven | Stem cell aggregates and methods for making and using |
| US20130129686A1 (en) * | 2009-11-19 | 2013-05-23 | Regents Of The University | Reducing Inflammation Using Cell Therapy |
| KR101900507B1 (ko) * | 2010-02-25 | 2018-09-19 | 에이비티 홀딩 컴퍼니 | 혈관신생의 조절 |
| WO2011106476A1 (en) * | 2010-02-25 | 2011-09-01 | Abt Holding Company | Modulation of microglia activation |
| SG10201913920PA (en) | 2010-05-12 | 2020-03-30 | Abt Holding Co | Modulation of splenocytes in cell therapy |
| US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| BR112013031368B1 (pt) * | 2011-06-06 | 2021-12-07 | ReGenesys BVBA | Método de expandir células ex vivo |
| US9901625B2 (en) | 2011-10-15 | 2018-02-27 | University Of Maryland, College Park | Methods of regulating uptake and transcellular transport of leukocytes and therapeutics |
| WO2013123084A1 (en) * | 2012-02-13 | 2013-08-22 | Minerva Biotechnologies Corporation | Method for detecting circulating fetal cells |
| IL289870B2 (en) | 2013-04-12 | 2023-03-01 | Lafrancesca Saverio | Improving organs for transplantation |
| CA3177726A1 (en) | 2015-05-21 | 2016-11-24 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
| JP6757981B2 (ja) * | 2015-07-02 | 2020-09-23 | ナンヤン テクノロジカル ユニヴァーシティー | 微少流体を用いる白血球および微小粒子分画 |
| KR20180102661A (ko) | 2016-01-21 | 2018-09-17 | 에이비티 홀딩 컴퍼니 | 상처 치유를 위한 줄기 세포 |
| US20210139932A1 (en) * | 2017-05-03 | 2021-05-13 | Biomarin Pharmaceutical Inc. | Improved lentiviruses for transduction of hematopoietic stem cells |
| WO2021194272A1 (ko) * | 2020-03-25 | 2021-09-30 | 울산과학기술원 | 질환 상태의 백혈구를 검출하거나, 백혈구 관련 질환을 진단하는 장치 또는 방법 |
| AU2021261282A1 (en) * | 2020-04-20 | 2022-11-24 | Longeveron Inc. | Potency assay |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
| JPH04500909A (ja) | 1988-09-21 | 1992-02-20 | アニマル バイオテクノロジー ケンブリッジ リミティド | 家畜からの多能性胚細胞系の誘導 |
| US7037721B1 (en) | 1990-01-29 | 2006-05-02 | Hy-Gene Biomedical, Inc. | Protein-free defined media for the growth of normal human keratinocytes |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5837539A (en) | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
| US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
| GB2254289B (en) | 1991-04-05 | 1995-03-22 | Gerber Garment Technology Inc | Readily transferrable adherent tape and methods of use and making |
| US5851832A (en) | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
| WO1993009220A1 (en) | 1991-11-06 | 1993-05-13 | Correa Paulo N | Cell culture medium |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
| AU4543193A (en) * | 1992-06-22 | 1994-01-24 | Henry E. Young | Scar inhibitory factor and use thereof |
| US5849553A (en) | 1992-07-27 | 1998-12-15 | California Institute Of Technology | Mammalian multipotent neural stem cells |
| US5564183A (en) | 1992-09-30 | 1996-10-15 | Matsushita Electric Industrial Co., Ltd. | Producing system of printed circuit board and method therefor |
| US7153684B1 (en) | 1992-10-08 | 2006-12-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
| US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
| US5766951A (en) | 1992-11-12 | 1998-06-16 | Quality Biological, Inc. | Serum-free medium supporting growth and proliferation of normal bone marrow cells |
| US5766948A (en) | 1993-01-06 | 1998-06-16 | The Regents Of The University Of California | Method for production of neuroblasts |
| US6037174A (en) | 1993-08-23 | 2000-03-14 | Nexell Therapeutics, Inc. | Preparation of serum-free suspensions of human hematopoietic cells or precursor cells |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US6432711B1 (en) | 1993-11-03 | 2002-08-13 | Diacrin, Inc. | Embryonic stem cells capable of differentiating into desired cell lines |
| FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US5914268A (en) | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| US5874301A (en) | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
| GB9502022D0 (en) * | 1995-02-02 | 1995-03-22 | Abuljadayel Ilham M S | A method for preparing lymphohaematopoietic progenitor cells |
| US5906934A (en) * | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
| US6653134B2 (en) * | 1995-03-28 | 2003-11-25 | Cp Hahnemann University | Isolated stromal cells for use in the treatment of diseases of the central nervous system |
| US5837670A (en) | 1995-04-18 | 1998-11-17 | Hartshorn; Richard Timothy | Detergent compositions having suds suppressing properties |
| US5908782A (en) | 1995-06-05 | 1999-06-01 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
| US6015554A (en) | 1995-06-07 | 2000-01-18 | Systemix, Inc. | Method of reconstituting human lymphoid and dendritic cells |
| EP0888377B1 (en) * | 1996-03-08 | 2007-12-12 | The Regents Of The University Of Michigan | MURINE alpha(1,3)-FUCOSYLTRANSFERASE (Fuc-TVII) |
| US6190910B1 (en) | 1996-05-21 | 2001-02-20 | The Institute Of Physical And Chemical Research | Mouse embryonic stem cell lines |
| US5753506A (en) | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
| US5827740A (en) | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
| US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
| US6361996B1 (en) | 1997-05-07 | 2002-03-26 | University Of Utah Research Foundation | Neuroepithelial stem cells and glial-restricted intermediate precursors |
| AU7984498A (en) | 1997-06-25 | 1999-01-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Serum-free cell growth medium |
| CA2294737A1 (en) | 1997-07-04 | 1999-01-14 | University Of Utah Research Foundation | Neuron-restricted precursor cells |
| ATE307195T1 (de) * | 1997-07-14 | 2005-11-15 | Osiris Therapeutics Inc | Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| EP1066052B1 (en) * | 1998-03-18 | 2006-02-01 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| US6368636B1 (en) * | 1998-03-18 | 2002-04-09 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| US6797269B2 (en) * | 1998-04-03 | 2004-09-28 | Osiris Therapeutics, Inc. | Mesenchymal stem cells as immunosuppressants |
| SE9802264D0 (sv) * | 1998-06-25 | 1998-06-25 | Neuronova Ab | A method of isolating cells |
| US6541247B1 (en) * | 1998-06-25 | 2003-04-01 | Neuronova Ab | Method of isolating ependymal neural stem cells |
| DE69933579D1 (de) | 1998-11-09 | 2006-11-23 | Consorzio Per La Gestione Del | Serum-freies medium für chondrozyt-ähnliche zellen |
| JP2002529070A (ja) | 1998-11-09 | 2002-09-10 | モナシュ・ユニヴァーシティ | 胚性幹細胞 |
| JP2002529508A (ja) * | 1998-11-13 | 2002-09-10 | オシリス セラピューティクス，インコーポレイテッド | 移植における免疫応答抑制のための線維芽細胞または線維芽細胞からの上澄みを使用する方法とその組成物 |
| US6777231B1 (en) * | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
| US20050153442A1 (en) | 1999-03-10 | 2005-07-14 | Adam Katz | Adipose-derived stem cells and lattices |
| US20050169896A1 (en) * | 1999-05-14 | 2005-08-04 | Henry Ford Health System | Bone marrow transplantation for treatment of stroke |
| US8075881B2 (en) * | 1999-08-05 | 2011-12-13 | Regents Of The University Of Minnesota | Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure |
| US8147824B2 (en) * | 1999-08-05 | 2012-04-03 | Athersys, Inc. | Immunomodulatory properties of multipotent adult progenitor cells and uses thereof |
| US7015037B1 (en) * | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| AU7611500A (en) * | 1999-09-24 | 2001-04-24 | Abt Holding Company | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
| NZ518601A (en) * | 1999-09-24 | 2004-10-29 | Morphogen Pharmaceuticals Inc | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
| US20030161817A1 (en) * | 2001-03-28 | 2003-08-28 | Young Henry E. | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
| US6685936B2 (en) * | 1999-10-12 | 2004-02-03 | Osiris Therapeutics, Inc. | Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation |
| EP1257282A4 (en) * | 1999-12-06 | 2003-05-02 | Gen Hospital Corp | PANCREATIC STEM CELLS AND THEIR USE IN TRANSPLANTATION |
| US7582292B2 (en) * | 2000-02-26 | 2009-09-01 | Artecel, Inc. | Adipose tissue derived stromal cells for the treatment of neurological disorders |
| DE60132429T2 (de) * | 2000-02-26 | 2009-01-08 | Artecel, Inc. | Pluripotente aus von fettgewebe stammenden stromazellen erzeugte stammzellen und deren verwendung |
| CA2411914C (en) | 2000-06-20 | 2012-08-21 | Es Cell International Pte Ltd | Method of controlling differentiation of embryonic stem (es) cells by culturing es cells in the presence of bmp-2 pathway antagonists |
| US20020061587A1 (en) * | 2000-07-31 | 2002-05-23 | Piero Anversa | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| AU2001296705A1 (en) * | 2000-10-06 | 2002-04-15 | The Regents Of The University Of California | Blocking inflammation by inhibiting sialylation |
| US7560280B2 (en) | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
| US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| DK1349918T3 (da) * | 2000-12-06 | 2014-11-10 | Anthrogenesis Corp | Fremgangsmåde til indsamling af stamceller fra moderkagen |
| IL157350A0 (en) * | 2001-02-14 | 2004-02-19 | Anthrogenesis Corp | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| EP1367899A4 (en) * | 2001-02-14 | 2004-07-28 | Leo T Furcht | TOTIPOTENT ADULT STEM CELLS, SOURCES OF SUCH CELLS, METHODS FOR OBTAINING AND MAINTAINING SAME, METHODS FOR DIFFERENTIATING THESE CELLS, METHODS OF USING SAME, AND CELLS DERIVED FROM THE ABOVE-MENTIONED CELLS |
| US7056738B2 (en) * | 2001-03-23 | 2006-06-06 | Tulane University | Early stage multipotential stem cells in colonies of bone marrow stromal cells |
| KR100449141B1 (ko) * | 2001-04-19 | 2004-09-21 | (주)라이프코드 | 간엽 간세포를 신경세포로 분화시키는 방법 |
| US20030003090A1 (en) * | 2001-05-31 | 2003-01-02 | Prockop Darwin J. | Directed in vitro differentiation of marrow stromal cells into neural cell progenitors |
| KR20040030161A (ko) | 2001-08-23 | 2004-04-08 | 리라이언스 라이프 사이언시스 프라이빗. 리미티드 | 인간 배 줄기 세포(ｈＥＳＣ)주를 확립하기 위한 내부세포 덩어리의 분리 방법 |
| US9969980B2 (en) * | 2001-09-21 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
| US6703279B2 (en) | 2002-01-04 | 2004-03-09 | Promos Technologies, Inc. | Semiconductor device having contact of Si-Ge combined with cobalt silicide |
| WO2003064598A2 (en) | 2002-01-25 | 2003-08-07 | Genzyme Corporation | Serum-free media for chondrocytes and methods of use thereof |
| US7145057B2 (en) | 2002-02-01 | 2006-12-05 | Origen Therapeutics, Inc. | Chimeric bird from embryonic stem cells |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| WO2003080197A1 (en) | 2002-03-20 | 2003-10-02 | Sara Griffin | Sports training device |
| GB0221481D0 (en) | 2002-09-16 | 2002-10-23 | Richards John M | Grip for hand held instruments |
| JP2006509770A (ja) * | 2002-11-26 | 2006-03-23 | アンソロジェネシス コーポレーション | 細胞治療学、細胞治療単位、およびそれらを利用した治療法 |
| US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| WO2004069172A2 (en) * | 2003-01-30 | 2004-08-19 | The Government of the United States of America as represented by the Department of Veterans Affairs | Multilineage-inducible cells and uses thereof |
| US20040235165A1 (en) * | 2003-05-19 | 2004-11-25 | Darwin Prockop | In vitro differentiation of adult stem cells |
| CA2528115A1 (en) * | 2003-06-03 | 2004-12-16 | Nancy L. Parenteau | Selection and propagation of progenitor cells |
| WO2005041944A2 (en) * | 2003-06-27 | 2005-05-12 | Schepens Eye Research Institute | Methods and compositions for promoting axon regeneration and cell replacement therapy |
| US20060210544A1 (en) * | 2003-06-27 | 2006-09-21 | Renomedix Institute, Inc. | Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient |
| ES2552226T3 (es) * | 2003-06-27 | 2015-11-26 | DePuy Synthes Products, Inc. | Reparación y regeneración de cartílago y hueso utilizando células derivadas posparto |
| EP1648935A2 (en) * | 2003-07-25 | 2006-04-26 | Amgen Inc. | Antagonists and agonists of ldcam and methods of use |
| ITRM20030376A1 (it) * | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| AU2004269409A1 (en) * | 2003-08-29 | 2005-03-10 | Regents Of The University Of Minnesota | Kidney derived stem cells and methods for their isolation, differentiation and use |
| WO2005025502A2 (en) * | 2003-09-08 | 2005-03-24 | Yeda Research And Development Co. Ltd. | A method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration |
| US9403908B2 (en) * | 2003-09-29 | 2016-08-02 | The Regents Of The University Of California | Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration |
| US8124072B2 (en) * | 2003-09-29 | 2012-02-28 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
| US20050089513A1 (en) * | 2003-10-28 | 2005-04-28 | Norio Sakuragawa | Side population cells originated from human amnion and their uses |
| US20080095749A1 (en) * | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
| WO2005093044A1 (en) * | 2004-03-22 | 2005-10-06 | Osiris Therapeutics, Inc. | Mesenchymal stem cells and uses therefor |
| US7622108B2 (en) * | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
| WO2005112959A2 (en) * | 2004-05-17 | 2005-12-01 | Regents Of The University Of Minnesota | Use of umbilical cord blood stem cells to treat ischemic event |
| CN103655618A (zh) * | 2006-01-23 | 2014-03-26 | 阿特西斯公司 | 无附加的免疫抑制治疗的mapc治疗法 |
| CA2642826C (en) * | 2006-01-23 | 2019-01-08 | Athersys, Inc. | Mapc treatment of brain injuries and diseases |
| US20080194637A1 (en) * | 2006-11-02 | 2008-08-14 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| CA2700457A1 (en) * | 2007-10-01 | 2009-04-09 | Austin Smith | Neural tumor stem cells and methods of use thereof |
| US20090130092A1 (en) * | 2007-10-30 | 2009-05-21 | Pinsky David J | Nucleotide phosphate dissipation as a treatment for vascular disorders |
-
2010
- 2010-07-21 AU AU2010276201A patent/AU2010276201B2/en active Active
- 2010-07-21 KR KR1020187002646A patent/KR20180014224A/ko not_active Ceased
- 2010-07-21 EP EP20203941.8A patent/EP3831930A1/en active Pending
- 2010-07-21 KR KR1020127004539A patent/KR101962477B1/ko not_active Expired - Fee Related
- 2010-07-21 CN CN201510188056.9A patent/CN104962512B/zh active Active
- 2010-07-21 CN CN201080041878.XA patent/CN102625829B/zh not_active Expired - Fee Related
- 2010-07-21 US US12/840,722 patent/US20110020293A1/en not_active Abandoned
- 2010-07-21 SG SG10201913624YA patent/SG10201913624YA/en unknown
- 2010-07-21 SG SG2012004156A patent/SG178064A1/en unknown
- 2010-07-21 CA CA2768576A patent/CA2768576C/en active Active
- 2010-07-21 BR BR112012001329-7A patent/BR112012001329B1/pt not_active IP Right Cessation
- 2010-07-21 DK DK10802840.8T patent/DK2456853T3/da active
- 2010-07-21 JP JP2012521750A patent/JP6243119B2/ja active Active
- 2010-07-21 WO PCT/US2010/042726 patent/WO2011011500A1/en not_active Ceased
- 2010-07-21 SG SG10201404280XA patent/SG10201404280XA/en unknown
- 2010-07-21 EP EP10802840.8A patent/EP2456853B1/en active Active
-
2012
- 2012-01-19 IL IL217648A patent/IL217648B/en active IP Right Grant
-
2013
- 2013-10-10 US US14/051,164 patent/US20140037596A1/en not_active Abandoned
-
2014
- 2014-10-31 JP JP2014222204A patent/JP6325419B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-18 JP JP2016082666A patent/JP2016129523A/ja active Pending
-
2018
- 2018-02-16 JP JP2018025725A patent/JP2018086011A/ja not_active Withdrawn
-
2019
- 2019-11-01 JP JP2019199927A patent/JP2020028298A/ja not_active Withdrawn
-
2021
- 2021-08-30 JP JP2021139876A patent/JP2021182941A/ja not_active Withdrawn
-
2023
- 2023-05-26 JP JP2023087113A patent/JP2023099831A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2768576C (en) | Use of stem cells to reduce leukocyte extravasation | |
| CA2768573C (en) | A method for constructing a cell bank and a method for drug discovery | |
| AU2011220940B2 (en) | Modulation of angiogenesis | |
| AU2013231210B2 (en) | Use of stem cells to reduce leukocyte extravasation | |
| HK40055177A (en) | Use of stem cells to reduce leukocyte extravasation | |
| HK1165489B (en) | Use of stem cells to reduce leukocyte extravasation | |
| HK1165489A (en) | Use of stem cells to reduce leukocyte extravasation | |
| AU2013237687B2 (en) | Use of stem cells to reduce leukocyte extravasation | |
| HK1165488A (en) | Use of stem cells to reduce leukocyte extravasation | |
| HK1165488B (en) | Use of stem cells to reduce leukocyte extravasation | |
| AU2016256806A1 (en) | Modulation of angiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150721 |
|
| EEER | Examination request |
Effective date: 20150721 |
|
| EEER | Examination request |
Effective date: 20150721 |
|
| EEER | Examination request |
Effective date: 20150721 |